Pennington Partners & CO. LLC Acquires 479 Shares of Eli Lilly and Company $LLY

Pennington Partners & CO. LLC grew its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 187.8% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 734 shares of the company’s stock after acquiring an additional 479 shares during the quarter. Pennington Partners & CO. LLC’s holdings in Eli Lilly and Company were worth $675,000 at the end of the most recent quarter.

A number of other hedge funds have also recently made changes to their positions in LLY. GC Wealth Management RIA LLC boosted its stake in shares of Eli Lilly and Company by 1.0% in the 1st quarter. GC Wealth Management RIA LLC now owns 19,837 shares of the company’s stock valued at $18,245,000 after purchasing an additional 192 shares in the last quarter. Public Employees Retirement System of Ohio raised its position in Eli Lilly and Company by 0.3% in the 1st quarter. Public Employees Retirement System of Ohio now owns 326,802 shares of the company’s stock worth $300,583,000 after purchasing an additional 1,043 shares during the period. Keebeck Wealth Management raised its position in Eli Lilly and Company by 4.0% in the 1st quarter. Keebeck Wealth Management now owns 6,552 shares of the company’s stock worth $6,026,000 after purchasing an additional 249 shares during the period. Arrowstreet Capital Limited Partnership lifted its stake in Eli Lilly and Company by 68.7% in the first quarter. Arrowstreet Capital Limited Partnership now owns 282,798 shares of the company’s stock worth $260,109,000 after purchasing an additional 115,132 shares during the last quarter. Finally, Wills Financial Group LLC boosted its position in Eli Lilly and Company by 21.6% during the first quarter. Wills Financial Group LLC now owns 1,019 shares of the company’s stock valued at $1,035,000 after buying an additional 181 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. Citigroup lifted their price objective on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Truist Financial increased their target price on Eli Lilly and Company from $1,281.00 to $1,370.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Bank of America raised their price target on Eli Lilly and Company from $1,251.00 to $1,334.00 and gave the stock a “buy” rating in a research report on Friday, July 10th. Weiss Ratings raised Eli Lilly and Company from a “buy (b-)” rating to a “buy (b)” rating in a research note on Wednesday, July 1st. Finally, Morgan Stanley boosted their price objective on Eli Lilly and Company from $1,344.00 to $1,347.00 and gave the company an “overweight” rating in a research report on Wednesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,283.64.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Retatrutide met its primary endpoints in two additional Phase 3 trials, with patients losing up to about 20.8% to 22.6% of body weight, strengthening the case for a highly valuable new obesity franchise. Reuters: Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application
• Positive Sentiment: Lilly said it now plans to file for FDA approval in the first quarter of 2027, keeping the drug on track for a potential future launch even though the filing was pushed back. CNBC: Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials
• Neutral Sentiment: Lilly is also expanding its pipeline through the acquisition of AtaiBeckley, a psychedelic medicine biotech, which could support longer-term diversification but is not an immediate earnings driver. Motley Fool: Eli Lilly Is Acquiring a Psychedelic Medicine Biotech. Here’s What You Need to Know.
• Negative Sentiment: The FDA filing for retatrutide was delayed from an earlier timeline, and Lilly said it needs more manufacturing and quality-control data, which adds a modest regulatory timing risk. Yahoo Finance: Lilly to file for next-gen obesity drug approval in early 2027
• Negative Sentiment: Novo Nordisk has filed a lawsuit accusing Lilly of misleading weight-loss advertising, creating headline legal risk in the competitive obesity-drug market. Yahoo Finance: How Novo Nordisk’s GLP-1 Advertising Lawsuit Against Eli Lilly (LLY) Has Changed Its Investment Story

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock opened at $1,185.31 on Friday. The company has a current ratio of 1.50, a quick ratio of 1.10 and a debt-to-equity ratio of 1.26. The firm has a 50-day moving average of $1,132.74 and a 200-day moving average of $1,039.05. The firm has a market cap of $1.12 trillion, a P/E ratio of 42.11, a P/E/G ratio of 1.47 and a beta of 0.51. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,249.45.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, April 30th. The company reported $8.55 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.97 by $1.58. Eli Lilly and Company had a return on equity of 105.77% and a net margin of 34.98%.The company had revenue of $19.80 billion for the quarter, compared to analysts’ expectations of $17.82 billion. During the same period last year, the firm earned $3.34 earnings per share. Eli Lilly and Company’s quarterly revenue was up 55.5% on a year-over-year basis. Eli Lilly and Company has set its FY 2026 guidance at 35.500-37.000 EPS. Sell-side analysts expect that Eli Lilly and Company will post 34.21 EPS for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Stockholders of record on Friday, August 14th will be paid a dividend of $1.73 per share. The ex-dividend date of this dividend is Friday, August 14th. This represents a $6.92 annualized dividend and a dividend yield of 0.6%. Eli Lilly and Company’s payout ratio is 24.58%.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.